Please login to the form below

Not currently logged in
Email:
Password:

Rigel Pharmaceuticals

This page shows the latest Rigel Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Rigel shaken after fostamatinib misses phase III trial target

Rigel shaken after fostamatinib misses phase III trial target

Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... In August, Rigel reported the same 18

Latest news

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    Rigel plans job cuts in R&D restructure. Follows failure of fostamatinib disodium in rheumatoid arthritis trial. ... Rigel Pharmaceuticals plans to cut 30 jobs as part of a restructure of its research efforts following the failure of fostamatinib

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    Pharma and Omthera Pharmaceuticals. ... Other respiratory prospects for AZ include the JAK inhibitor R256 licensed last year from Rigel Pharmaceuticals in a deal that could be worth up to $100m.

  • AstraZeneca strikes $100m deal for chronic asthma candidate AstraZeneca strikes $100m deal for chronic asthma candidate

    AstraZeneca strikes $100m deal for chronic asthma candidate. Licenses Rigel Pharmaceuticals' inhaled JAK inhibitor R256. ... AstraZeneca (AZ) has licensed a pre-clinical candidate for chronic asthma from clinical-stage drug development company Rigel

  • Pfizer returns asthma drug to Rigel

    Pfizer returns asthma drug to Rigel. Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals. ... Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals as part of a

  • AZ's phase III RA trial underway

    Fostamatinib was initially developed by Rigel Pharmaceuticals, with AZ purchasing rights to further develop and commercialise the drug in February 2010.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Salix Pharmaceuticals/ Valeant Pharmaceuticals. GI products. Corporate acquisition. 14, 500. Flexus Biosciences/ BMS. ... Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors -

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics